Cantor Fitzgerald Investment Advisors L.P. acquired 4,510 shares of Elevance Health during the third quarter, representing an investment of approximately $1.46 million. This marks the firm’s first reported stake in the health benefits provider. Other institutions have also adjusted their holdings: Vermillion & White Wealth Management Group nearly doubled its position to 76 shares in Q2, Glass Jacobson Investment Advisors increased its stake by 400% to 100 shares, and several smaller managers added new positions valued between $30,000 and $61,000. Hedge funds and institutional investors now collectively own over 89% of the company’s shares.

Elevance Health reported third-quarter earnings per share of $6.03, surpassing the consensus forecast of $5.03 by 20%. Revenue climbed 12.0% year-over-year to $50.09 billion, outpacing analyst projections of $49.26 billion. While net margin contracted to 2.84%, return on equity remained robust at 16.17%, underscoring efficient capital deployment. The company’s disciplined cost management and premium growth in Medicare and Medicaid managed-care lines drove the beat, setting the stage for anticipated full-year EPS of roughly $33.96.

Elevance Health finished the quarter with a debt-to-equity ratio of 0.71 and both quick and current ratios at 1.56, reflecting ample liquidity. In December, the board declared a quarterly dividend of $1.71 per share, translating to an annualized payout of $6.84 and a yield near 2.0%, supported by a payout ratio of 27.96%. Among 23 analysts covering the stock, 12 maintain Buy ratings, 11 hold, and 1 recommend Sell, with an average price target of $396.21. Recent revisions include a rise in target from $360 to $398 by one major bank and a reduction from $435 to $425 by another, highlighting divergent views on near-term valuation catalysts.